CHEMOCENTRYX INC (CCXI)
US16383L1061 - Common Stock
CHEMOCENTRYX INC
NASDAQ:CCXI (10/19/2022, 7:04:24 PM)
After market: 51.99 0 (0%)51.99
+0.03 (+0.06%)
Company Profile
ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. The company is headquartered in San Carlos, California and currently employs 178 full-time employees. The company went IPO on 2012-02-08. The firm is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The firm's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. The company markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
Company Info
CHEMOCENTRYX INC
835 Industrial Road, Suite 600
San Carlos CALIFORNIA 94043
P: 16502102900.0
CEO: Thomas J. Schall
Employees: 178
Website: https://www.chemocentryx.com/
CCXI News
2 years ago - AmgenAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with...
2 years ago - ChemoCentryx, Inc.ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and...
2 years ago - ChemoCentryx, Inc.ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2 years ago - Investor's Business DailyHere Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This YearThe biotech run off a June bottom is great — until you realize you could've netted more.
CCXI Twits
Here you can normally see the latest stock twits on CCXI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
